For Research Use Only.

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a recently identified coronavirus strain responsible for the Coronavirus Disease 2019 (COVID-19) and pandemic. SARS-CoV-2 is transmitted mainly through droplets and surface contact routes. The virus infects human cells through interaction between angiotensin converting enzyme 2 (ACE2) on respiratory cells and spike or S-protein on the outer envelope of the virion particle. Symptoms can include signs and symptoms of acute respiratory illness, such as fever, cough, shortness of breath, but patients can also present as asymptomatic. The Simoa™ SARS-CoV-2 Spike IgG Advantage Kit is intended for the detection of human IgG antibodies to SARS-CoV-2 in serum or EDTA plasma. The test detects IgG antibodies that may be indicative of an immune response to SARS-CoV-2 in patients suspected of previous SARS-CoV-2 infection, or for the detection of IgG seroconversion in patients following known recent SARS-CoV-2 exposure. For research use only. Not for diagnostic procedures.